ModernVivo’s AI Aims to Unclog the Drug Discovery Pipeline

SEATTLE, WA – September 15, 2026 – In the high-stakes, multi-billion-dollar race to bring new drugs to market, time is the most valuable and unforgiving currency. A significant portion of that time is consumed in the preclinical phase, a complex labyrinth of in vivo studies where promising compounds are vetted before they can even be considered for human trials. Today, Seattle-based ModernVivo announced a new service aimed squarely at one of this phase's most notorious bottlenecks: finding the right partner to run the experiments.

The company has launched the ModernVivo Marketplace, a free-to-use platform designed to connect pharmaceutical and biotech researchers with Contract Research Organizations (CROs) in days, not the months this process typically takes. While CRO marketplaces are not a new concept, ModernVivo’s approach represents a critical operational innovation by integrating deep scientific context into the matchmaking process, potentially reshaping a fundamental step in drug development.

The Preclinical Logjam

The challenge ModernVivo is tackling is both vast and well-documented. The preclinical CRO market, valued at over $5 billion in 2022, is projected to nearly double by 2030, driven by an industry-wide push to outsource R&D for efficiency and specialized expertise. However, this outsourcing trend has created its own set of inefficiencies.

The preclinical stage itself can span three to six years, and selecting the right CRO is one of the most consequential decisions a development team makes. An improper choice can lead to flawed data, regulatory delays, and wasted capital. The search process is often a manual, resource-intensive slog involving extensive research, lengthy Requests for Proposals (RFPs), and protracted negotiations.

“It’s a major pain point,” explained a senior director of preclinical development at a Cambridge-based biotech firm, who spoke on condition of anonymity. “You can spend two to three months just identifying and qualifying a CRO with the specific animal models and assay capabilities you need. For a small company where every week counts, that delay is brutal.” This problem is compounded by the increasing complexity of modern therapeutics, which often require highly specialized and difficult-to-find technical expertise.

An AI Matchmaker for Science

ModernVivo’s solution is to replace this manual search with an intelligent, data-driven platform. The company’s core product, ModernVivo Scholar, is a literature intelligence tool that uses AI to analyze millions of peer-reviewed publications, helping scientists design their in vivo studies by identifying relevant models and experimental conditions. The new Marketplace is a natural extension of this capability.

Instead of matching based on broad categories like "oncology" or "immunology," the Marketplace leverages the granular details of a study design—the specific animal models, endpoints, and protocol requirements—to find a CRO. This deep-seated understanding of the project's scientific needs is the platform's key differentiator. It promises to connect researchers not just with a capable CRO, but with the best-fit CRO for their unique experiment.

"We are the only platform that not only helps teams design their study but also facilitates connections to the groups that can actually execute the experiment," said Ian Levine, Co-Founder and CEO at ModernVivo, in the company's announcement. "Our goal is to make development as seamless as possible... Ultimately, this product will mean faster drug development, helping potential cures and treatments reach the clinic sooner."

By pre-vetting its network of CROs across North America, Europe, and Asia-Pacific, the platform aims to remove the guesswork and instill confidence, allowing research teams to move from design to execution with unprecedented speed.

Reshaping Business for CROs

The Marketplace is not just a tool for drug developers; it represents a significant shift in the business development landscape for CROs. In the traditional model, CROs expend considerable resources responding to broad RFPs, many of which are poor fits for their core competencies. This results in a low-yield, high-effort sales cycle.

ModernVivo’s platform flips the script. By matching based on specific technical capabilities, it delivers pre-qualified, high-intent leads directly to the CROs best equipped to handle them. This allows CROs with niche specializations to become instantly visible to relevant clients, bypassing the noise of the general market.

For a mid-sized CRO specializing in a particular type of neurological disease model, for instance, the platform could be a game-changer. Instead of competing on name recognition or marketing budget, they can compete on the basis of their unique scientific expertise. This levels the playing field and ensures that the most qualified organization for a given study is found, regardless of its size or marketing prowess. It transforms the sales process from a wide-net search into a precision engagement.

Accelerating the Path to the Clinic

The downstream implications of solving this matchmaking problem are profound. Shaving months off the preclinical timeline does more than just save money on a single project; it accelerates the entire drug development pipeline. In an industry where only one in ten candidates makes it from preclinical to clinical trials, speed is paramount.

Faster CRO selection allows companies to generate critical data sooner, enabling quicker go/no-go decisions and accelerating the preparation of Investigational New Drug (IND) applications for regulatory bodies. For venture-backed biotech companies, hitting milestones ahead of schedule can be the difference between securing the next round of funding and closing up shop.

By reducing a key source of friction in early-stage R&D, ModernVivo is addressing a systemic inefficiency that has long plagued the industry. If the platform delivers on its promise to shrink the CRO selection process from a months-long marathon to a days-long sprint, it will not only provide a competitive advantage to its users but also contribute to a more agile and efficient ecosystem for discovering the next generation of medicines.